Biocodex USA hired Dr. Andres Tellez as principal, business development and strategy, responsible for in-licensing or acquiring new therapeutics to market for the US subsidiary of Biocodex, a French pharmaceutical firm.
3-V Biosciences promoted Stephen Brady to chief business officer. Brady joined the firm in 2010 as VP, corporate development, strategy & operations, with management responsibility for the company’s business functions. Prior to joining 3-V, he was VP of corporate development for Proteolix. Brady also worked at Lexicon Pharmaceuticals, where he served in business development, communications and corporate legal capacities, and was a VP with Lazard Venture Advisors, a division of Lazard Freres & Co.
